PMID- 31348323
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 30
DP  - 2019 Jul
TI  - Comparison of efficacy and safety of S-1 and capecitabine in patients with 
      metastatic colorectal carcinoma: A systematic review and meta-analysis.
PG  - e16667
LID - 10.1097/MD.0000000000016667 [doi]
LID - e16667
AB  - BACKGROUND: This study aimed to compare the efficacy and safety of S-1 and 
      capecitabine in patients with metastatic colorectal carcinoma (mCRC). METHODS: 
      Eligible prospective clinical trials were searched and available data were 
      extracted. Odds ratio and hazard ratio of available outcomes including objective 
      response rate (ORR), disease control rate (DCR), progression-free survival (PFS), 
      overall survival (OS), and adverse events (AEs) were pooled for analysis. 
      RESULTS: A total of 6 studies including 828 patients were included. The results 
      of pooled analysis showed no statistical difference in short-term efficacy 
      including ORR (95% confidence interval [CI]: 0.68-1.19; P = .48) or DCR (95% CI: 
      0.65-1.29; P = .61), or long-term efficacy including PFS (95% CI: 0.75-1.08; 
      P = .26) or OS (95% CI: 0.78-1.13; P = .50). Symptoms of diarrhea at any grade 
      were more prevalent (95% CI: 1.21-2.29; P = .002) in patients treated with S-1, 
      while hand-foot syndrome (HFS) at any grade (95% CI: 0.24-0.48; P < .0001) or 
      high grade (95% CI: 0.09-0.48; P < .0001) was more frequent in capecitabine 
      group. AEs including leucopenia, neutropenia, anemia, thrombocytopenia, vomiting, 
      oral mucositis, stomatitis, elevated alanine transaminase, or peripheral 
      neuropathy showed no statistical difference between S-1 and capecitabine group 
      (all P > .05). CONCLUSIONS: This meta-analysis reveals that S-1 has comparable 
      efficacy, lower risk of HFS and higher incidence of diarrhea compared to 
      capecitabine for treatment in patients with mCRC.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Medical Oncology.
FAU - Wang, Junhui
AU  - Wang J
AD  - Department of Radiation Oncology.
FAU - Xu, Tiancai
AU  - Xu T
AD  - Department of Gastroenterology, Quzhou People's Hospital, Quzhou, Zhejiang, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
RN  - 6804DJ8Z9U (Capecitabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Capecitabine/administration & dosage/adverse effects/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/*pathology
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Oxonic Acid/administration & dosage/adverse effects/*therapeutic use
MH  - Proportional Hazards Models
MH  - Randomized Controlled Trials as Topic
MH  - Survival Analysis
MH  - Tegafur/administration & dosage/adverse effects/*therapeutic use
PMC - PMC6709012
EDAT- 2019/07/28 06:00
MHDA- 2019/08/14 06:00
PMCR- 2019/07/26
CRDT- 2019/07/27 06:00
PHST- 2019/07/27 06:00 [entrez]
PHST- 2019/07/28 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2019/07/26 00:00 [pmc-release]
AID - 00005792-201907260-00098 [pii]
AID - MD-D-18-09007 [pii]
AID - 10.1097/MD.0000000000016667 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jul;98(30):e16667. doi: 10.1097/MD.0000000000016667.